Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Wyeth/Santaris, Novartis/HHS, Cephalon/Ception ...

Executive Summary

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

You may also be interested in...



People In The News – Tracking The Latest Industry Personnel Moves

New top leadership at Pulmatrix, Althea and Mucosis; McKesson names Mark Walchirk president of U.S. pharma business; Former FDA Deputy Commissioner Scott Gottlieb joins Aptiv board. More personnel announcements in this month’s column.

Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says

Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.

Co-Development Deal Brings Bristol A Novel Interferon, ZymoGenetics Much-Needed Cash

Formerly legal adversaries, the two companies will co-develop PEG-interferon lambda, currently in Phase Ib for hepatitis C.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel